Cogent Biosciences prices $150M common stock offering of 12.5M shares at $12.00/share

Cogent Biosciences, Inc.

Offers 12,500,000 shares of common stock at $12.00 per share; gross proceeds ~$150M.
Underwriters granted 30-day option to purchase up to 1,875,000 additional shares on same terms.
Underwriting syndicate led by J.P. Morgan, Jefferies, Piper Sandler, and Guggenheim Securities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cogent Biosciences, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at $150 million (effective 2023-06-06).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters
Value: $150 million
Effective: 2023-06-06

Exact text from the filing

On June 6, 2023, Cogent Biosciences, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 12,500,000 shares of the Company’s common stock at a public offering price of $12.00 per share (the “Offering”).

View on SEC.gov

Browse all material agreements →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-163546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.